In this issue:
HRR mutations, especially BRCA1/2, are adverse prognostic features in mCRPC
REASSURE: 223Ra safe and effective for bone-dominant mCRPC in real-world
Elderly patients at high clinical suspicion of malignancy may not require pre-imaging biopsy
Putative biomarkers of metastatic disease in Black men identified
PROCLAIM supports universal comprehensive genetic testing
MRI detects prostate cancer missed by PSA screening
CONTACT-02: Cabozantinib + atezolizumab combo promising for mCRPC
PBAC recommendations
FDA approves niraparib and abiraterone acetate for BRCA-mutated mCRPC
No benefit to xentuzumab + enzalutamide combo in mCRPC
Facility case volume impacts survival in very high-risk disease
BCR endpoints are not a valid surrogate for survival
COVID-19 resources
Conferences & Workshops
Please login below to download this issue (PDF)